{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:19:36Z","timestamp":1783480776757,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16141-9","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:53:57Z","timestamp":1778576037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy of first- and second-generation EGFR TKIs in NSCLC with EGFR co-mutations: a Vietnamese cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Luong","family":"Van Dinh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc B\u00edch Thi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung Quoc","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieu Huy","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang Doan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh Tu","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"16141_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"16141_CR2","doi-asserted-by":"publisher","first-page":"1611715","DOI":"10.3389\/pore.2024.1611715","volume":"30","author":"G Galffy","year":"2024","unstructured":"Galffy G, et al. Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol Oncol Res. 2024;30:1611715. https:\/\/doi.org\/10.3389\/pore.2024.1611715.","journal-title":"Pathol Oncol Res"},{"key":"16141_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","volume":"6","author":"G da Cunha Santos","year":"2011","unstructured":"da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49\u201369. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130206.","journal-title":"Annu Rev Pathol"},{"key":"16141_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lungcan.2017.08.021","volume":"113","author":"B Han","year":"2017","unstructured":"Han B, et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer. 2017;113:37\u201344. https:\/\/doi.org\/10.1016\/j.lungcan.2017.08.021.","journal-title":"Lung Cancer"},{"key":"16141_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s43556-022-00107-x","volume":"3","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Mol Biomed. 2022;3:42. https:\/\/doi.org\/10.1186\/s43556-022-00107-x.","journal-title":"Mol Biomed"},{"key":"16141_CR6","doi-asserted-by":"publisher","unstructured":"Chhouri H, Alexandre D, Grumolato L. Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15020504.","DOI":"10.3390\/cancers15020504"},{"key":"16141_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(16)30033-X.","journal-title":"Lancet Oncol"},{"key":"16141_CR8","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(17)30608-3.","journal-title":"Lancet Oncol"},{"key":"16141_CR9","doi-asserted-by":"publisher","unstructured":"Reita D, et al. Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13194926.","DOI":"10.3390\/cancers13194926"},{"key":"16141_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390\u2013401. https:\/\/doi.org\/10.1016\/j.apsb.2015.07.001.","journal-title":"Acta Pharm Sin B"},{"key":"16141_CR11","doi-asserted-by":"publisher","unstructured":"Travis WD et al. International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 6 (2011\/02\/01). https:\/\/doi.org\/10.1097\/JTO.0b013e318206a221.","DOI":"10.1097\/JTO.0b013e318206a221"},{"key":"16141_CR12","unstructured":"Health V. M. o. Vol. 4825\/QD-BYT. 2018."},{"key":"16141_CR13","doi-asserted-by":"publisher","unstructured":"Schwartz LH et al. RECIST 1.1 \u2013 Update and Clarification: From the RECIST Committee. Eur J cancer (Oxford, England: 1990). 2016;62. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081.","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"16141_CR14","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985\u201393. https:\/\/doi.org\/10.18632\/oncotarget.12587.","journal-title":"Oncotarget"},{"key":"16141_CR15","doi-asserted-by":"publisher","unstructured":"Takeda M, Nakagawa K. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20010146.","DOI":"10.3390\/ijms20010146"},{"key":"16141_CR16","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/j.cllc.2019.05.003","volume":"20","author":"SC Lau","year":"2019","unstructured":"Lau SC, Chooback N, Ho C, Melosky B. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. Clin Lung Cancer. 2019;20:e576\u201383. https:\/\/doi.org\/10.1016\/j.cllc.2019.05.003.","journal-title":"Clin Lung Cancer"},{"key":"16141_CR17","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.tranon.2019.07.008","volume":"12","author":"SC Chang","year":"2019","unstructured":"Chang SC, et al. Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. Transl Oncol. 2019;12:1425\u201331. https:\/\/doi.org\/10.1016\/j.tranon.2019.07.008.","journal-title":"Transl Oncol"},{"key":"16141_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2019.09.017","volume":"137","author":"ACZ Gelatti","year":"2019","unstructured":"Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113\u201322. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.017.","journal-title":"Lung Cancer"},{"key":"16141_CR19","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-19-0780","volume":"25","author":"A Truini","year":"2019","unstructured":"Truini A, et al. The EGFR Exon 19 Mutant L747-A750\u2009>\u2009P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. Clin Cancer Res. 2019;25:6382\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0780.","journal-title":"Clin Cancer Res"},{"key":"16141_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research, N","year":"2014","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543\u201350. https:\/\/doi.org\/10.1038\/nature13385.","journal-title":"Nature"},{"key":"16141_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","volume":"14","author":"Y Kim","year":"2019","unstructured":"Kim Y, et al. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. J Thorac Oncol. 2019;14:193\u2013202. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.150.","journal-title":"J Thorac Oncol"},{"key":"16141_CR22","doi-asserted-by":"publisher","first-page":"e14799","DOI":"10.1016\/j.heliyon.2023.e14799","volume":"9","author":"M Takahashi","year":"2023","unstructured":"Takahashi M, et al. Activating mutations in EGFR and PI3K promote ATF4 induction for NSCLC cell survival during amino acid deprivation. Heliyon. 2023;9:e14799. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e14799.","journal-title":"Heliyon"},{"key":"16141_CR23","first-page":"629","volume":"1","author":"H Endoh","year":"2006","unstructured":"Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol. 2006;1:629\u201334.","journal-title":"J Thorac Oncol"},{"key":"16141_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1097\/JTO.0000000000000671","volume":"10","author":"J Eng","year":"2015","unstructured":"Eng J, et al. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. J Thorac Oncol. 2015;10:1713\u20139. https:\/\/doi.org\/10.1097\/JTO.0000000000000671.","journal-title":"J Thorac Oncol"},{"key":"16141_CR25","doi-asserted-by":"publisher","unstructured":"BS K, et al. Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer - PubMed. Tumori. 2019 Jun;105. https:\/\/doi.org\/10.1177\/0300891619839292.","DOI":"10.1177\/0300891619839292"},{"key":"16141_CR26","unstructured":"Ferlay J, Lam EM, Laversanne F, Colombet M, Mery M, Pi\u00f1eros L, Znaor M, Soerjomataram A, Bray I. F Global Cancer Observatory: Cancer Today. 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/704-viet-nam-fact-sheet.pdf."},{"key":"16141_CR27","doi-asserted-by":"publisher","unstructured":"DW B, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms - PubMed. Clin cancer research: official J Am Association Cancer Res.2008;14. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5030.","DOI":"10.1158\/1078-0432.CCR-07-5030"},{"key":"16141_CR28","doi-asserted-by":"publisher","unstructured":"J X, L, Z., B, H., Q C. Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis - PubMed. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.01531.","DOI":"10.3389\/fonc.2020.01531"},{"key":"16141_CR29","doi-asserted-by":"publisher","unstructured":"Huang Y-H et al. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Scientific Reports. 2021;11:1. https:\/\/doi.org\/10.1038\/s41598-021-91657-7.","DOI":"10.1038\/s41598-021-91657-7"},{"key":"16141_CR30","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s41388-020-01597-1","volume":"40","author":"FJ Cheng","year":"2021","unstructured":"Cheng FJ, et al. Cigarette smoke-induced LKB1\/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. Oncogene. 2021;40:1162\u201375. https:\/\/doi.org\/10.1038\/s41388-020-01597-1.","journal-title":"Oncogene"},{"key":"16141_CR31","doi-asserted-by":"publisher","unstructured":"Zhang Y et al. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis. Clin Lung Cancer. 2015;16:144-151 e141. https:\/\/doi.org\/10.1016\/j.cllc.2014.09.008.","DOI":"10.1016\/j.cllc.2014.09.008"},{"key":"16141_CR32","doi-asserted-by":"publisher","unstructured":"Shetty V, Babu S. Management of CNS metastases in patients with EGFR mutation-positive NSCLC. Indian J Cancer. 2019;56. https:\/\/doi.org\/10.4103\/ijc.IJC_455_19.","DOI":"10.4103\/ijc.IJC_455_19"},{"key":"16141_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3892\/ol.2025.14947","volume":"29","author":"CC Hsu","year":"2025","unstructured":"Hsu CC, et al. Clinical outcome analysis of different first\u2013 and second\u2013generation EGFR\u2013tyrosine kinase inhibitors in untreated patients with EGFR\u2013mutated non\u2013small cell lung cancer with baseline brain metastasis. Oncol Lett. 2025;29:201. https:\/\/doi.org\/10.3892\/ol.2025.14947.","journal-title":"Oncol Lett"},{"key":"16141_CR34","doi-asserted-by":"publisher","unstructured":"Attili I, et al. New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations. Cancers. 2023;15. https:\/\/doi.org\/10.3390\/cancers15205079.","DOI":"10.3390\/cancers15205079"},{"key":"16141_CR35","doi-asserted-by":"publisher","unstructured":"Caponnetto S et al. A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. J Mol Pathol. 2021;2:1\u201310. https:\/\/doi.org\/10.3390\/jmp2010001.","DOI":"10.3390\/jmp2010001"},{"key":"16141_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/oncolo\/oyae043","volume":"29","author":"G Pasello","year":"2024","unstructured":"Pasello G, et al. Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World. Oncologist. 2024;29:596\u2013608. https:\/\/doi.org\/10.1093\/oncolo\/oyae043.","journal-title":"Oncologist"},{"key":"16141_CR37","doi-asserted-by":"publisher","first-page":"1288468","DOI":"10.3389\/fonc.2023.1288468","volume":"13","author":"W Gu","year":"2023","unstructured":"Gu W, et al. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs. Front Oncol. 2023;13:1288468. https:\/\/doi.org\/10.3389\/fonc.2023.1288468.","journal-title":"Front Oncol"},{"key":"16141_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","volume":"135","author":"M Ge","year":"2017","unstructured":"Ge M, et al. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J Neurooncol. 2017;135:413\u20138. https:\/\/doi.org\/10.1007\/s11060-017-2590-x.","journal-title":"J Neurooncol"},{"key":"16141_CR39","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.4103\/jcrt.jcrt_1986_21","volume":"19","author":"R Thomas","year":"2023","unstructured":"Thomas R, et al. Molecular epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: A single-center experience from India. J Cancer Res Ther. 2023;19:1398\u2013406. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1986_21.","journal-title":"J Cancer Res Ther"},{"key":"16141_CR40","doi-asserted-by":"publisher","first-page":"860563","DOI":"10.3389\/fonc.2022.860563","volume":"12","author":"S Liu","year":"2022","unstructured":"Liu S, Yu J, Zhang H, Liu J. TP53 Co-Mutations in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. Front Oncol. 2022;12:860563. https:\/\/doi.org\/10.3389\/fonc.2022.860563.","journal-title":"Front Oncol"},{"key":"16141_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-023-10637-4","volume":"23","author":"H Sun","year":"2023","unstructured":"Sun H, et al. Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study. BMC Cancer. 2023;23:198. https:\/\/doi.org\/10.1186\/s12885-023-10637-4.","journal-title":"BMC Cancer"},{"key":"16141_CR42","doi-asserted-by":"publisher","unstructured":"JS T, et al. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma - PubMed. Lung cancer (Amsterdam Netherlands). 2015;90. https:\/\/doi.org\/10.1016\/j.lungcan.2015.09.024.","DOI":"10.1016\/j.lungcan.2015.09.024"},{"key":"16141_CR43","doi-asserted-by":"publisher","unstructured":"YK C, et al. The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations - PubMed. J Thorac disease. 2016;8. https:\/\/doi.org\/10.21037\/jtd.2016.11.25.","DOI":"10.21037\/jtd.2016.11.25"},{"key":"16141_CR44","doi-asserted-by":"publisher","unstructured":"M, J.-H, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer - PubMed. N Engl J Med. 2017;376. https:\/\/doi.org\/10.1056\/NEJMoa1616288.","DOI":"10.1056\/NEJMoa1616288"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16141-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16141-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:04:15Z","timestamp":1783479855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16141-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16141"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16141-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8735835\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by a state-level scientific research project titled \u201cResearch on the application of artificial intelligence and next-generation sequencing technologies in detecting gene mutations associated with targeted therapy response in common cancers in Vietnam\u201d (KC-4.0-42\/19\u201325). It was approved by the Institutional Review Board Hanoi Medical University. Due to the retrospective nature of the study and the use of anonymized data, the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. As this was a retrospective study utilizing de-identified clinical data, the Institutional Review Board of Hanoi Medical University waived the requirement for individual informed consent. All authors have reviewed the final version of the manuscript and provide their formal consent for its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"822"}}